Skip to main content

IOVA Iovance Biotherapeutics, Inc.

Healthcare

7.74 USD 1D -0.96 -11.03% Close 11/5
Since 2024-12-05 +2.7%

Close 11/5

Open
8.40
High
8.75
Low
7.64
Prev close
8.70
Volume
23.31M
Amplitude
12.76%
P/B
5.3
Revenue YoY (TTM)
+34.5%
52W 2.08 15.37
FinLab Studio

From Iovance Biotherapeutics, Inc. to every stock like it

AI finds several complementary traits of Iovance Biotherapeutics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Iovance Biotherapeutics, Inc.

Is Iovance Biotherapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-11-04

Growth: Good, Momentum: Strong; Valuation: Pricey, Quality: Weak.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -12.4 N/A
Price / book 5.4 84th percentile · Expensive
Free-cash-flow yield (%) -7.5 30th percentile · Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Weak All 3 indicators are Lagging.
ROE, TTM (%) -39.3 20th percentile · Lagging
Operating margin, TTM (%) -92.7 14th percentile · Lagging
FCF margin, TTM (%) -91.2 14th percentile · Lagging
Quality Factor Investing: A US Quality Value Backtest
Growth Good Revenue growth, TTM YoY is Top, but Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 34.6 83th percentile · Top
Diluted EPS growth, TTM YoY (%) -43.1 38th percentile · Average
Momentum Strong All 2 indicators are Top.
60-day return (%) 34.0 97th percentile · Top
240-day return (%) 284.8 99th percentile · Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Lagging.
20-day dollar volume 177,421,529.0 91th percentile · Top
60-day annualized volatility (%) 124.6 88th percentile · Lagging
Factor Investing Explained: 10 Classic Factors in US Stocks

Iovance Biotherapeutics, Inc. (IOVA) today

2 quant signals active · As of 2026-11-04

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Iovance Biotherapeutics, Inc. (IOVA) peers and tracking

Watchlist

This page refreshes daily after the close. Add Iovance Biotherapeutics, Inc. to your watchlist to track signal changes on your next visit.

Iovance Biotherapeutics, Inc. (IOVA) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 98.6%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
21 historical occurrences (since 2016-07-12)

Average forward return after Top-quintile 6-month momentum

20-day: Win 57.1%, Sample 21, Median +2.8%, Excess +10.2%, Beat mkt rate 52.4%

60-day: Win 61.9%, Sample 21, Median +15.2%, Excess +15.9%, Beat mkt rate 57.1%

120-day: Win 55.0%, Sample 20, Median +7.0%, Excess +10.1%, Beat mkt rate 50.0%

120 days after: historical avg +17.3%

20-day +10.2%
60-day +18.2%
120-day +17.3%
20-day
60-day
120-day
Win
57.1%
61.9%
55.0%
Sample
21
21
20
Median
+2.8%
+15.2%
+7.0%
Excess
+10.2%
+15.9%
+10.1%
Beat mkt rate
52.4%
57.1%
50.0%

Over 20 occurrences, 120-day forward avg gained 17.3%, beat the market by 10.1 pts; win rate 55.0%.

Filed revenue acceleration

Active · now 34.5%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

2 historical occurrences (since 2025-02-27)
More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 100,217 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.37%, a 58.3% positive-return rate, and +3.03 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

16 times historically; 60-day forward avg +21.2%, win rate 57.1%, beating the market by +18.4 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

17 times historically; 60-day forward avg +8.8%, win rate 56.2%, beating the market by +5.0 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.